A new clinical trial consisting of a 4-drug chemotherapy combination has resulted in considerable extensions in lifespan for early-stage pancreatic cancer patients. According to trial results, median survival rate of patients who were administered the new drug regimen was 4.5 years. While authors of the trial mentioned that 75% of patients experienced more serious side-effects after taking the new experimental drug combination (compared to 53% of those on standard chemotherapy treatment), they remain cautiously optimistic that this new drug discovery is "an important step forward."
To read more about this trial, click here.
No comments:
Post a Comment